<div id="readability-page-1">NovoCure (NVCR) is scheduled to announce Q1 earnings results on Thursday, April 30th, before market open. The consensus EPS Estimate is -$0.51 (-64.5% Y/Y) and the consensus Revenue Estimate is $167.77M (+8.2% Y/Y). Over the last 2 years, NVCR has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time. Over the last 3...</div>

NVCR

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>NovoCure (NVCR) 將於 4 月 30 日公佈其第一季度財報，市場普遍預期每股收益（EPS）為-0.51 美元，同比下降 64.5%；預計收入為 1.6777 億美元，同比增加 8.2%。在過去兩年中，該公司有 63% 的時間超出每股收益和收入預期</p>

NovoCure Q1 2026 earnings preview

NovoCure

NovoCure 2026 年第一季度財報預覽